Recently, TrialSite News commented on a telling IQVIA survey showcasing the rise of “Emerging Biopharma.” In what used to be solely the territory of “big pharma,” new agile, aggressive and often well-funded private equity-based emerging biopharma operate on the same level. In 2018, 64% of the 59 new active substances commercialized in 2018 were originated by emerging biopharma. Moreover, just last year 47% of new active substances were launched by emerging biopharma—a fundamental change from a decade ago. The rise of the emerging biopharma could possibly reshape the CRO landscape.
Hence, we read with interest a recent Applied Clinical Trials interview titled “The Changing Needs of Mid-sized Sponsors.” Editors interviewed Becky Carpenter, Head of North American/Euro Operations at WuXi Clinical, originally launched out of China and now an increasingly well-branded mid-market CRO. WuXi Clinical is the result of a merger between Research Point Global and WuXi Clinical Development Services.
We encourage the reader to select the link at the bottom to read the entire interview. In a nutshell, we provide a summary of Ms. Carpenter key market themes.
WuXi Mid-Market CRO Trends Obser...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).